简体中文 | 繁體中文 | English

Health and Pharmaceutical Press Releases

2024-02-28 14:11 BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
2024-02-28 13:56 Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
2024-02-28 13:46 ReNAgade Therapeutics Appoints Joe Bolen, Ph.D., Chief Science Innovation Officer
2024-02-27 12:55 MHRA Issues Notice of Acceptance for POLARIS-AD, a Phase 3 Early Alzheimer’s Disease Trial Sponsored by AriBio Co., Ltd.
2024-02-27 12:09 Caldera Medical's Humanitarian Effort Reaches New Heights: 400,000 Women Treated Worldwide
2024-02-26 09:44 Celltrion presents new two-year data for subcutaneous infliximab (CT-P13 SC) in inflammatory bowel disease (IBD) at the 19th ECCO Congress
2024-02-26 09:37 Neuraptive Therapeutics, Inc. Announces Positive 24-Week Data for NTX-001 in the Phase 2 NEUROFUSE Study, Reinforcing Previously Announced Proof of Concept 12-Week Data
2024-02-23 11:41 New Swiss Made Features for Cataract Surgery Lens Selection
2024-02-23 11:18 ReNAgade Therapeutics to Present at the Evercore ISI 2024 Emerging Biotech Conference
2024-02-22 15:24 Parse Biosciences Launches Evercode Whole Transcriptome Version 3, Boosting Usability and Performance
2024-02-22 10:11 TriLink BioTechnologies® Solidifies IP Position with Awarded Patents for CleanCap® Capping Technology in China and Canada
2024-02-22 09:45 MMI Raises $110 Million in Series C Financing
2024-02-21 16:24 Sinovac Amends Shareholder Rights Plan
2024-02-21 13:27 AI Medical Service Inc. Completes First Regulatory Review and Device Registration of Gastric AI-based Endoscopic Diagnosis Support System from Singapore’s HSA
2024-02-21 13:24 MRM Health Initiates Clinical Research in Parkinson’s Disease
2024-02-21 11:27 Patient Safety Movement Foundation Outlines 2024 Action Plan for Creating a Safer Healthcare System
2024-02-21 10:00 Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement
2024-02-18 15:51 CORRECTING and REPLACING, Galderma Announces Regulatory Filing Acceptance for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in the U.S. and EU
2024-02-18 09:58 Perfect Moment Announces Closing of Initial Public Offering
2024-02-09 11:47 Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Business Wire Weibo

Press Releases

Latest Releases